JP2018538246A - Ａｃｃ阻害剤およびその使用 - Google Patents

Ａｃｃ阻害剤およびその使用 Download PDF

Info

Publication number
JP2018538246A
JP2018538246A JP2018521087A JP2018521087A JP2018538246A JP 2018538246 A JP2018538246 A JP 2018538246A JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018521087 A JP2018521087 A JP 2018521087A JP 2018538246 A JP2018538246 A JP 2018538246A
Authority
JP
Japan
Prior art keywords
grams
membered
ring
independently selected
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018521087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538246A5 (enExample
Inventor
ショミール ゴーシュ，
ショミール ゴーシュ，
ジェラルディン シー． ハリマン，
ジェラルディン シー． ハリマン，
デ モラデイ， シルヴァーナ マルセル レイト
デ モラデイ， シルヴァーナ マルセル レイト
ジェレミー アール． グリーンウッド，
ジェレミー アール． グリーンウッド，
Original Assignee
ギリアド アポロ， エルエルシー
ギリアド アポロ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアド アポロ， エルエルシー, ギリアド アポロ， エルエルシー filed Critical ギリアド アポロ， エルエルシー
Publication of JP2018538246A publication Critical patent/JP2018538246A/ja
Publication of JP2018538246A5 publication Critical patent/JP2018538246A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2018521087A 2015-10-26 2016-10-26 Ａｃｃ阻害剤およびその使用 Pending JP2018538246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246318P 2015-10-26 2015-10-26
US62/246,318 2015-10-26
PCT/US2016/058867 WO2017075056A1 (en) 2015-10-26 2016-10-26 Acc inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2018538246A true JP2018538246A (ja) 2018-12-27
JP2018538246A5 JP2018538246A5 (enExample) 2019-12-05

Family

ID=57233943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018521087A Pending JP2018538246A (ja) 2015-10-26 2016-10-26 Ａｃｃ阻害剤およびその使用

Country Status (14)

Country Link
US (2) US10179793B2 (enExample)
EP (1) EP3368540A1 (enExample)
JP (1) JP2018538246A (enExample)
KR (1) KR20180067603A (enExample)
CN (1) CN108368125A (enExample)
AR (1) AR106472A1 (enExample)
AU (1) AU2016344392A1 (enExample)
BR (1) BR112018008227A2 (enExample)
CA (1) CA3003275A1 (enExample)
EA (1) EA201890749A1 (enExample)
IL (1) IL258636A (enExample)
MX (1) MX2018005292A (enExample)
SG (1) SG11201802989QA (enExample)
WO (1) WO2017075056A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021112213A1 (ja) * 2019-12-05 2021-06-10 日本曹達株式会社 ２，４－ジオキソ－１，４－ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤
JP2022551014A (ja) * 2019-12-05 2022-12-06 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Ａｃｃ１及びａｃｃ２阻害剤としての結晶形及びその製造方法並びに使用

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2776038T1 (en) 2011-11-11 2018-06-29 Gilead Apollo, Llc ACC INHIBITORS AND THEIR USE
CA2968935C (en) 2014-11-26 2023-03-07 Takeda Pharmaceutical Company Limited Bicyclic compound having an acetyl-coa carboxylase (acc) inhibitory activity
JP2019503338A (ja) 2015-11-25 2019-02-07 ギリアド アポロ， エルエルシー ２，４−ジオキソ−１，４−ジヒドロチエノ［２，３−ｄ］ピリミジンの誘導体を含む殺真菌組成物
AU2016361414A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Ester ACC inhibitors and uses thereof
PT3380479T (pt) 2015-11-25 2023-03-13 Gilead Apollo Llc Inhibidores de triazol acc e seus usos
JP2019502660A (ja) 2015-11-25 2019-01-31 ギリアド アポロ， エルエルシー ピラゾールａｃｃ阻害剤およびその使用
SG11201807077RA (en) * 2016-03-02 2018-09-27 Gilead Apollo Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
SG11201902588PA (en) 2016-09-23 2019-05-30 Bayer Ag N3-Cyclically Substituted Thienouracils And Use Thereof
WO2018133858A1 (en) 2017-01-22 2018-07-26 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
AU2018227575A1 (en) * 2017-03-03 2019-09-19 Gilead Apollo, Llc Processes for the preparation of fungicidal compounds
US20180280394A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
CN110709402B (zh) * 2017-06-15 2022-05-10 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
CN109305976B (zh) * 2017-07-26 2022-07-01 南京圣和药业股份有限公司 作为acc抑制剂的化合物及其应用
WO2019191451A1 (en) 2018-03-30 2019-10-03 Biotheryx, Inc. Thienopyrimidinone compounds
US11680070B2 (en) 2018-06-05 2023-06-20 Medshine Discovery Inc. Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof
CA3118422A1 (en) * 2018-11-02 2020-05-07 Dow Agrosciences Llc Compositions comprising halauxifen and other herbicides and methods thereof
AU2019385438A1 (en) * 2018-11-20 2021-05-27 The National Institutes of Pharmaceutical R&D Co., Ltd. Spiro compound and medical uses thereof
CN111484504B (zh) * 2019-01-25 2024-05-10 南京圣和药业股份有限公司 Acc抑制剂的光学异构体及其应用
WO2020197926A1 (en) * 2019-03-22 2020-10-01 Kallyope, Inc. Gpcr combination therapies
US12428432B2 (en) 2019-07-02 2025-09-30 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN110746439B (zh) * 2019-10-18 2020-10-30 南京瑞捷医药科技有限公司 一种噻吩并嘧啶二酮化合物的制备方法
JP7198968B2 (ja) * 2019-12-05 2023-01-04 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 チエノ［２，３－ｃ］ピリダジン－４（１Ｈ）－オン系化合物の結晶形及びその製造方法並びに使用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN113968871A (zh) * 2020-07-25 2022-01-25 南京圣和药业股份有限公司 苯基取代类acc抑制剂的晶型
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels
WO2022138812A1 (ja) 2020-12-24 2022-06-30 モジュラス株式会社 テトラヒドロチエノピリミジンスルホンアミド化合物
WO2022268520A1 (de) * 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.
CN115677551A (zh) * 2021-12-28 2023-02-03 武汉市振邦生物科技有限公司 一种2-氧代吡咯烷-3-甲酸乙酯的制备工艺
PE20250877A1 (es) 2022-08-05 2025-03-28 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
CN115433756B (zh) * 2022-08-30 2024-04-09 山东新华制药股份有限公司 一种泼尼松龙的制备方法
US20250276979A1 (en) * 2024-02-07 2025-09-04 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289583A (ja) * 1986-04-28 1987-12-16 オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン チエノピリミジン−２，４−ジオン誘導体類およびそれらの中間生成物類
US4835157A (en) * 1988-03-15 1989-05-30 Ortho Pharmaceutical Corporation Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents
JPH0761986A (ja) * 1990-02-22 1995-03-07 Takeda Chem Ind Ltd 縮合チオフェン誘導体
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
JP2003292492A (ja) * 2002-01-30 2003-10-15 Takeda Chem Ind Ltd チエノピリミジン化合物、その製造法および用途
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
WO2008143262A1 (ja) * 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02225485A (ja) 1989-02-27 1990-09-07 Taiho Yakuhin Kogyo Kk チエノピリミジン―３―酢酸誘導体
TW276256B (enExample) 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
JP3811196B2 (ja) 1993-08-26 2006-08-16 武田薬品工業株式会社 エンドセリン拮抗剤、チエノピリミジン誘導体およびその製造法
WO2000061583A1 (en) 1995-06-07 2000-10-19 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
JPH09110873A (ja) 1995-08-17 1997-04-28 Takeda Chem Ind Ltd チエノピリミジン誘導体、その製造法および用途
ATE227726T1 (de) 1995-08-17 2002-11-15 Takeda Chemical Industries Ltd Thienopyrimidinderivate als endothelin antagonisten
EP0906115A1 (en) 1996-04-30 1999-04-07 Takeda Chemical Industries, Ltd. COMBINED USE OF GnRH AGONIST AND ANTAGONIST
JP2007302703A (ja) 1996-04-30 2007-11-22 Takeda Chem Ind Ltd 医薬組成物
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
DE19754082A1 (de) 1997-12-05 1999-06-10 Knoll Ag Methode zur Bekämpfung der Fettleibigkeit
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
ES2246481T3 (es) 2002-02-27 2006-02-16 Pfizer Products Inc. Inhibidores de la acc.
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
ATE425668T1 (de) 2003-01-06 2009-04-15 Yissum Res Dev Co Pflanzliche acetyl-coa carboxylase-hemmende herbizide als pestizide
ES2410814T3 (es) 2003-01-29 2013-07-03 Takeda Pharmaceutical Company Limited Compuestos de tienopirimidina y uso de los mismos
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
EP1989210A2 (en) 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
PT2519527E (pt) 2009-12-29 2014-02-17 Poxel Tieno[2,3-b]piridinodiona como activadores de ampk e suas utilizações terapêuticas
WO2011143553A1 (en) * 2010-05-14 2011-11-17 University Of Rochester Compositions and methods for targeting a3g:rna complexes
JP6434498B2 (ja) 2013-05-10 2018-12-05 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
WO2014182951A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
AU2014262636A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
HK1221419A1 (zh) * 2013-05-10 2017-06-02 Gilead Apollo, Inc. Acc抑制剂和其用途
TWI652012B (zh) 2013-05-20 2019-03-01 杜邦股份有限公司 殺真菌吡唑的固態形式
WO2015007453A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
JP2019502660A (ja) 2015-11-25 2019-01-31 ギリアド アポロ， エルエルシー ピラゾールａｃｃ阻害剤およびその使用
AU2016361414A1 (en) 2015-11-25 2018-05-24 Gilead Apollo, Llc Ester ACC inhibitors and uses thereof
JP2019503338A (ja) 2015-11-25 2019-02-07 ギリアド アポロ， エルエルシー ２，４−ジオキソ−１，４−ジヒドロチエノ［２，３−ｄ］ピリミジンの誘導体を含む殺真菌組成物
PT3380479T (pt) 2015-11-25 2023-03-13 Gilead Apollo Llc Inhibidores de triazol acc e seus usos
SG11201807077RA (en) 2016-03-02 2018-09-27 Gilead Apollo Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289583A (ja) * 1986-04-28 1987-12-16 オ−ソ・フア−マシユ−チカル・コ−ポレ−シヨン チエノピリミジン−２，４−ジオン誘導体類およびそれらの中間生成物類
US4835157A (en) * 1988-03-15 1989-05-30 Ortho Pharmaceutical Corporation Thieno- and furopyrimidine-2,4-dione piperidine derivatives as serotonin antagonists and alpha adrenergic blocking agents
JPH0761986A (ja) * 1990-02-22 1995-03-07 Takeda Chem Ind Ltd 縮合チオフェン誘導体
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
JP2004518732A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としてのチエノ’２，３−ｄピリミジンジオン誘導体
JP2003292492A (ja) * 2002-01-30 2003-10-15 Takeda Chem Ind Ltd チエノピリミジン化合物、その製造法および用途
WO2008143262A1 (ja) * 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
JP2014533281A (ja) * 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2015007451A1 (en) * 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021112213A1 (ja) * 2019-12-05 2021-06-10 日本曹達株式会社 ２，４－ジオキソ－１，４－ジヒドロチエノピリミジン化合物、及びそれを含有する農園芸用殺菌剤又は医療用・動物用抗真菌剤
JP2022551014A (ja) * 2019-12-05 2022-12-06 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Ａｃｃ１及びａｃｃ２阻害剤としての結晶形及びその製造方法並びに使用
JP7265681B2 (ja) 2019-12-05 2023-04-26 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 Ａｃｃ１及びａｃｃ２阻害剤としての結晶形及びその製造方法並びに使用

Also Published As

Publication number Publication date
EA201890749A1 (ru) 2018-11-30
EP3368540A1 (en) 2018-09-05
AU2016344392A1 (en) 2018-05-10
KR20180067603A (ko) 2018-06-20
MX2018005292A (es) 2018-08-01
US20170145028A1 (en) 2017-05-25
CA3003275A1 (en) 2017-05-04
IL258636A (en) 2018-06-28
AR106472A1 (es) 2018-01-17
US10179793B2 (en) 2019-01-15
SG11201802989QA (en) 2018-05-30
US20190330224A1 (en) 2019-10-31
BR112018008227A2 (pt) 2018-10-23
WO2017075056A1 (en) 2017-05-04
CN108368125A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
US10179793B2 (en) ACC inhibitors and uses thereof
US10800791B2 (en) Triazole ACC inhibitors and uses thereof
US10941158B2 (en) Pyrazole ACC inhibitors and uses thereof
US11098055B2 (en) Ester ACC inhibitors and uses thereof
US10472374B2 (en) ACC inhibitors and uses thereof
HK1255652B (en) Acc inhibitors and uses thereof
HK1255652A1 (en) Acc inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210506